Login

First International PTCOG Ocular Proton Therapy Symposium 2022

3–4 Mar 2022
Europe/Zurich timezone

Contact person

Contribution List

35 / 35
11. Clinical audit of different radiation modalities and different proton beams for ocular tumors
Juliette Thariat
03/03/2022, 14:14
12. Ocular late effects in long term survivors of uveal melanoma in adult and AYA patients treated by proton therapy
Alessia Pica (PSI - Paul Scherrer Institut)
03/03/2022, 14:23
13. Management of ocular side effects following proton beam radiotherapy for uveal melanoma
Heinrich Heimann
03/03/2022, 14:32
10. Navigating Change and Improving Outcomes: Patient-Centered Strategies for the Next Decade
Kavita K. Mishra (University of California San Francisco)
03/03/2022, 14:41
15. Ophthalmic advances in proton beam radiotherapy for ocular tumours
Bertil Damato
03/03/2022, 15:14
17. Surgical experience and RT toxicity with a dedicated ocular beamline: Orsay experience
Nathalie Cassoux
03/03/2022, 15:23
18. Best practices from the Chicago Proton Center gantry set-up: Opportunities and Challenges
Rashmi Kapur
03/03/2022, 15:32
16. Surgical best practices and potential pitfalls for proton ocular RT: An ophthalmologist perspective
Ann Schalenbourg
03/03/2022, 15:41
5. Delivery of optimal ocular proton beams in the next decade?
Andrzej Kacperek (University College London)
03/03/2022, 16:20
1. The long-term Nice experience with a dedicated proton eyeline: what can we change without compromising clinical outcomes?
Joël Hérault (IMPT-Centre Antoine Lacassagne)
03/03/2022, 16:30
8. Treating ocular melanoma with a modified pencil-beam-scanning system: a dosimetric study
roelf slopsema (Emory University)
03/03/2022, 16:40
2. Characterization of the non-dedicated scanning proton beamline for ocular treatment and clinical workflow at CNAO
MARIO CIOCCA (Fondazione CNAO)
03/03/2022, 16:50
4. First experience in the Netherlands: Workflow, characterization and multicenter comparison of the HollandPTC ocular beamline
Kees Spruijt
03/03/2022, 17:00
7. Commissioning a commercial eye treatment solution - experience at WPE
Benjamin Koska (WPE)
03/03/2022, 17:20
6. Implementation of Gantry-Based Treatment at the Mayo Clinic: brass-free and auto-gated
Amanda Deisher (Mayo Clinic - Rochester)
03/03/2022, 17:30
3. 3-D planning and multi-field treatment without using an ocular beamline
William Hartsell (Northwestern Medicine Proton Center)
03/03/2022, 17:40
20. High resolution MR-imaging for ocular proton therapy planning
Jan-Willem Beenakker (Leiden University Medical Center)
04/03/2022, 14:04
21. MRI evaluation for proton beam treatment planning
Berit Verbist (Leiden University Medical Centre)
04/03/2022, 14:13
22. Strengths and weaknesses of different imaging modalities, an ophthalmologists perspective with focus on treatment planning
Antonia Joussen
04/03/2022, 14:22
23. From clip-based to clipless treatment
Jan Hrbacek (PSI - Paul Scherrer Institut)
04/03/2022, 14:31
26. EYEPLAN for Proton Radiation Therapy of Ocular Melanoma: UCSF Experience
Inder Daftari (University of California- San Francisco)
04/03/2022, 15:04
25. From EyePlan to Octopus: From model based to 3D planning
Jens Heufelder
04/03/2022, 15:13
27. Experience with the RayOcular TPS – from initial requirements to treated patients at WPE
Jörg Wulff
04/03/2022, 15:22
28. Planning Eye Treatments in a Spot Scanning Gantry with Monte Carlo Calculated Beamlets
Jon Kruse
04/03/2022, 15:31
29. Treatment planning systems for ocular treatment with carbon-ion beams
Nobuyuki Kanematsu (National Institutes for Quantum Science and Technology)
04/03/2022, 15:40
34. Overview of patient set-up and delivery with tips
Helen Shih (Massachusetts General Hospital)
04/03/2022, 16:14
32. A challenging case of a large conjunctival squamous cell carcinoma
Roi Dagan
04/03/2022, 16:23
33. CT based simulation utilizing MRI and scleral clips
Lia Halasz (University of Washington)
04/03/2022, 16:32
35. Proton Re-irradiation for Choroidal Melanomas
remi Dendale (INSTITUT CURIE ORSAY)
04/03/2022, 16:41
31. Eye Tracking technologies for positioning and motion management in Ocular Proton Therapy
Riccardo Via (PSI - Paul Scherrer Institut)
04/03/2022, 16:50
36. Spatially fractionated proton therapy for eye cancer - Feasibility study
Jan Swakon
04/03/2022, 17:24
40. QA of ocular treatments at Massachusetts General
Alexei Trofimov (Massachusetts General Hospital)
04/03/2022, 17:33
38. In-house developed tools for QA of dedicated ocular beam line
Jessica Scholey (University of California San Francisco)
04/03/2022, 17:42
37. Aspects of the Ocular Quality Assurance Program at the Centre de Protonthérapie d’Orsay
Catherine Nauraye
04/03/2022, 17:51
39. Daily QA procedures at UFHPTI
Maria Mamalui
04/03/2022, 18:00
Powered by Indico v3.3-pre